RecruitingPhase 2NCT06985147
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Studying Polycythemia vera
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Disc Medicine, Inc
- Principal Investigator
- Will Savage, MD PhDDisc Medicine
- Intervention
- DISC-3405(drug)
- Enrollment
- 60 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (14)
- Mayo Clinic in Arizona, Phoenix, Arizona, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA Health, Los Angeles, California, United States
- Keck Medicine of USC - Cancer Clinic- Newport Beach, Newport Beach, California, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Mayo Clinic in Minnesota, Rochester, Minnesota, United States
- Siteman Cancer Center - Washington University St. Louis, St Louis, Missouri, United States
- Atrium Health - Levine Cancer Center, Charlotte, North Carolina, United States
- Duke University, Durham, North Carolina, United States
- Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- University of Washington - Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06985147 on ClinicalTrials.govOther trials for Polycythemia vera
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)MPN Research Foundation
- RECRUITINGPHASE2NCT07232290Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGNCT06743035Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic SplenomegalyiOMEDICO AG
- RECRUITINGNCT06752941LOW-PV ContinuationFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE3NCT06093672Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraItalfarmaco
- RECRUITINGPHASE1NCT06752746A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraMabwell (Shanghai) Bioscience Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE3NCT06033586Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraProtagonist Therapeutics, Inc.
- RECRUITINGPHASE2NCT05870475Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVInstitute of Hematology & Blood Diseases Hospital, China